Phase 3 Clinical Trials

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

6 days ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide

1 week ago talkbio0Tagged Biotechnology, Goldman Sachs, Ironwood, Phase 3 Clinical Trials, plunge, regulatory hurdle, Short Bowel Syndrome, strategic alternatives, United States Food and Drug Administration

Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology

AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III

1 month ago talkbio0Tagged Amolyt, Calypso study, Eneboparatide, Hypoparathyroidism, Pharma Acquisition, Phase 3 Clinical Trials

eneboparatide, hypoparathyroidism, Phase III trial, Calypso study, Amolyt Pharma acquisition

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

2 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval

2 months ago talkbio0Tagged Approved, Boehringer, FIBRONEER-ILD, fibrosing, Improvement, Ingelheim, Inhibitor, nerandomilast, PF-ILDs, Phase 3 Clinical Trials, phosphodiesterase 4B, Progressive, Respiratory physiology, United States Food and Drug Administration

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor